Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2013

01.07.2013 | Clinical Study

Mood disturbance in glioma patients

verfasst von: A. A. Acquaye, E. Vera-Bolanos, T. S. Armstrong, M. R. Gilbert, L. Lin

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Patients diagnosed with primary brain tumors such as glioma experience psychological distress throughout the illness trajectory. Determining which patient characteristics are associated with more severe mood disturbance throughout the illness trajectory can help identify patients at risk and assist in developing targeted interventions based on these factors. Adult glioma patients were eligible for participation. Data collection tools included an investigator completed clinician assessment tool, patient completed demographic form and the Profile of mood states-short form. A multiple regression model was used to describe the relationship between the patient groups and clinical factors. The study enrolled 186 glioma patients of various tumor grades, who were categorized in three groups (newly diagnosed, on-treatment, follow-up) based on disease status at time of visit. Newly diagnosed patients experienced more total mood disturbance than all the other groups. Characteristics associated with more severe mood disturbance varied by patient group: newly diagnosed patients who were not on corticosteroids and were not married were more likely to have higher mood disturbance [R2 = 0.27, F (2, 29) = 5.31, p < 0.02]. For those on treatment, the use of concomitant medications, having more than 1 recurrence and low income predicted higher mood disturbance [R2 = 0.417, F (4, 67) = 11.98, p < 0.001]. For those not on active treatment, female sex, anti-depressant use and having a lower income was associated with higher mood disturbance [R2 = 0.183, F (3, 55) = 4.11, p < 0.02]. Additionally, when compared to other cancer groups, glioma patients reported similar mood disturbance to those with breast cancer. Factors other than disease characteristics are associated with higher mood disturbance and vary according to current disease status. The use of concomitant medications, demographic factors, recurrence and income are associated with mood disturbance and interventions may need to be tailored to these underlying factors.
Literatur
1.
Zurück zum Zitat American Cancer Society (2012) Cancer facts and figures 2012. American Cancer Society, Atlanta, Ga. Available online Last accessed 24 Sep 2012 American Cancer Society (2012) Cancer facts and figures 2012. American Cancer Society, Atlanta, Ga. Available online Last accessed 24 Sep 2012
2.
Zurück zum Zitat Dolecek TA, Propp JM, Stroup NE (2012) Kruchko, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. J Neurooncol 14(5):1–49 Dolecek TA, Propp JM, Stroup NE (2012) Kruchko, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. J Neurooncol 14(5):1–49
3.
Zurück zum Zitat Rooney AG, Carson A, Grant R (2011) Depression in cerebral glioma patients: a systematic review of observational studies. J Natl Cancer Inst 103(1):61–76PubMedCrossRef Rooney AG, Carson A, Grant R (2011) Depression in cerebral glioma patients: a systematic review of observational studies. J Natl Cancer Inst 103(1):61–76PubMedCrossRef
4.
Zurück zum Zitat Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J (2002) Predicting major depression in brain tumor patients. Psycho-Oncology 11:230–238PubMedCrossRef Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J (2002) Predicting major depression in brain tumor patients. Psycho-Oncology 11:230–238PubMedCrossRef
5.
Zurück zum Zitat Mainio A et al (2005) Depression and functional outcome in patients with brain tumors: a population-based 1-year follow-up study. J Neurosurg 103(5):841–847PubMedCrossRef Mainio A et al (2005) Depression and functional outcome in patients with brain tumors: a population-based 1-year follow-up study. J Neurosurg 103(5):841–847PubMedCrossRef
6.
Zurück zum Zitat Rooney AG, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, Grant R (2011) Frequency, clinical associations, and longitudinal course of major depressive disored in adults with cerebral glioma. J Clin Oncol 29(32):4307–4312PubMedCrossRef Rooney AG, McNamara S, Mackinnon M, Fraser M, Rampling R, Carson A, Grant R (2011) Frequency, clinical associations, and longitudinal course of major depressive disored in adults with cerebral glioma. J Clin Oncol 29(32):4307–4312PubMedCrossRef
7.
Zurück zum Zitat Pringle AM, Taylor R, Whittle IR (1999) Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. Br J Neurosurg 13(1):46–51PubMedCrossRef Pringle AM, Taylor R, Whittle IR (1999) Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. Br J Neurosurg 13(1):46–51PubMedCrossRef
8.
Zurück zum Zitat Lin L et al (2012) Validation of the Mishel’s uncertainty in illness scale-brain tumor form (MUIS-BT). J Neurooncol Lin L et al (2012) Validation of the Mishel’s uncertainty in illness scale-brain tumor form (MUIS-BT). J Neurooncol
9.
Zurück zum Zitat Baker F et al (2002) A POMS short form for cancer patients: psychometric and structural evaluation. Psychooncology 11(4):273–281PubMedCrossRef Baker F et al (2002) A POMS short form for cancer patients: psychometric and structural evaluation. Psychooncology 11(4):273–281PubMedCrossRef
10.
Zurück zum Zitat Armstrong TS et al (2006) Validation of the M.D. anderson symptom inventory brain tumor module (MDASI-BT). J Neurooncol 80(1):27–35PubMedCrossRef Armstrong TS et al (2006) Validation of the M.D. anderson symptom inventory brain tumor module (MDASI-BT). J Neurooncol 80(1):27–35PubMedCrossRef
11.
Zurück zum Zitat Armstrong TS et al (2009) Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manage 37(3):331–340PubMedCrossRef Armstrong TS et al (2009) Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manage 37(3):331–340PubMedCrossRef
12.
Zurück zum Zitat Gould R, Brown SL, Bramwell R (2010) Psychological adjustment to gynaecological cancer: patients’ illness representations, coping strategies and mood disturbance. Psychol Health 25(5):633–649PubMedCrossRef Gould R, Brown SL, Bramwell R (2010) Psychological adjustment to gynaecological cancer: patients’ illness representations, coping strategies and mood disturbance. Psychol Health 25(5):633–649PubMedCrossRef
13.
Zurück zum Zitat Rottmann N, Dalton SO, Bidstrup PE, Wurtzen H, Hoybye MT, Ross L, Christensen J, Frederiksen K, Hansen DG, Johansen C (2011) No improvement in distress and quality of life following psychosocial cancer rehabilitation. A randomised trial. Psycho-Oncology 21:505–514PubMedCrossRef Rottmann N, Dalton SO, Bidstrup PE, Wurtzen H, Hoybye MT, Ross L, Christensen J, Frederiksen K, Hansen DG, Johansen C (2011) No improvement in distress and quality of life following psychosocial cancer rehabilitation. A randomised trial. Psycho-Oncology 21:505–514PubMedCrossRef
14.
Zurück zum Zitat Conti CM et al (2011) Relationship between cancer and psychology: an updated history. J Biol Regul Homeost Agents 25(3):331–339PubMed Conti CM et al (2011) Relationship between cancer and psychology: an updated history. J Biol Regul Homeost Agents 25(3):331–339PubMed
16.
17.
Zurück zum Zitat Shi Q et al (2011) Symptom burden in cancer survivors 1 year after diagnosis: a report from the American cancer society’s studies of cancer survivors. Cancer 117(12):2779–2790PubMedCrossRef Shi Q et al (2011) Symptom burden in cancer survivors 1 year after diagnosis: a report from the American cancer society’s studies of cancer survivors. Cancer 117(12):2779–2790PubMedCrossRef
18.
Zurück zum Zitat Markman M, Luce R (2010) Impact of the cost of cancer treatment: an internet-based survey. J Oncol Pract 6(2):69–73PubMedCrossRef Markman M, Luce R (2010) Impact of the cost of cancer treatment: an internet-based survey. J Oncol Pract 6(2):69–73PubMedCrossRef
Metadaten
Titel
Mood disturbance in glioma patients
verfasst von
A. A. Acquaye
E. Vera-Bolanos
T. S. Armstrong
M. R. Gilbert
L. Lin
Publikationsdatum
01.07.2013
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2013
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-013-1143-1

Weitere Artikel der Ausgabe 3/2013

Journal of Neuro-Oncology 3/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.